Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium

Vaccine

Volumn 31, Issue 37, 2013, Pages 3962-3971

  Demarteau, Nadia ^a   Van Kriekinge, Georges ^a   Simon, Philippe ^b  

^a GSK   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Adult; Belgium; Cervical cancer; Cost effectiveness; Human papillomavirus; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENCE; ADOLESCENT; ARTICLE; BELGIUM; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG COST; FEMALE; HEALTH CARE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NORMAL HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER; VACCINATION;

ADULT; BELGIUM; CARCINOMA IN SITU; CC; CERVICAL CANCER; CERVICAL INTRAEPITHELIAL NEOPLASIA; CIN; CIS; COST-EFFECTIVENESS; GDP; GROSS DOMESTIC PRODUCT; HPV; HUMAN PAPILLOMAVIRUS; ICER; INCREMENTAL COST-EFFECTIVENESS RATIO; QALY; QUALITY-ADJUSTED LIFE-YEAR; TOTAL VACCINATED COHORT; TVC; VACCINATION; VACCINE EFFICACY; VE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGE FACTORS; AGED; BELGIUM; CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; CROSS PROTECTION; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84881545929     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.008     Document Type: Article

References (51)

1. Arbyn M., Castellsague X., de S.S., Bruni L., Saraiya M., Bray F., et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011, 22(December (12)):2675-2686.
2. Arbyn M., Raifu A.O., Autier P., Ferlay J. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007, 18(October (10)):1708-1715.
3. Belgian Cancer Registry Annual new diagnoses 2008, Available from URL: http://kankerregister.nettools.be/default.aspx?url=p_130.htm [cited 27.12.2011].
4. Annemans L., Remy V., Lamure E., Spaepen E., Lamotte M., Muchada J.P., et al. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium. J Med Econ 2008, 11(1):135-150.
5. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(September (1)):12-19.
6. Thiry N., De Laet C., Hulstaert F., Neyt M., Huybrechts M., Cleemput I. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care 2009, 25(April (2)):161-170.
7. Paavonen J., Naud P., Salmeron J., Wheeler C., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(July (9686)):301-314.
8. Skinner R., Apter D., Chow S.N., Wheeler C., Dubin G. Cross-protective efficacy of Cervarix against oncogenic HPV types beyond HPV-16/18: final analysis of cross-protection - PATRICIA study. Presented at the 25th international papillomavirus conference 2009.
9. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199(April (7)):926-935.
10. Szarewski A. Cervarix(R): a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types. Expert Rev Vaccines 2012, 11(June (6)):645-657.
11. Malagón T., Drolet M., Boily M.C., Franco E.L., Jit M., Brisson J., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(10):781-789.
12. Simoens C., Sabbe M., Van Damme P., Beutels P., Arbyn M. Introduction of human papillomavirus (HPV) vaccination in Belgium, 2007-2008. Euro Surveill 2009, 14(46). pii: 19407.
13. Brotherton J.M., Fridman M., May C.L., Chappell G., Saville A.M., Gertig D.M. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377(June (9783)):2085-2092.
14. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56(March (RR-2)):1-24.
15. Demarteau N., Detournay B., Tehard B., El Hasnaoui A., Standaert B. A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int J Public Health 2011, 56(April (2)):153-162.
16. Annemans L., Remy V., Oyee J., Largeron N. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 2009, 27(3):231-245.
17. de Peuter M.A., Littlewood K.J., Annemans L., Largeron N., Quilici S. Cost-effectiveness of catch-up programs in human papillomavirus vaccination. Expert Rev Vaccines 2010, 9(October (10)):1187-1201.
18. Debicki D., Ferko N., Demarteau N., Gallivan S., Bauch C., Anonychuk A., et al. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine 2008, 26(Suppl 5):F16-F28.
19. Van Hentenryck M., Noel J.C., Simon P. Obstetric and neonatal outcome after surgical treatment of cervical dysplasia. Eur J Obstet Gynecol Reprod Biol 2012, 162(May (1)):16-20.
20. Wellings K., Collumbien M., Slaymaker E., Singh S., Hodges Z., Patel D., et al. Sexual behaviour in context: a global perspective. Lancet 2006, 368(November (9548)):1706-1728.
21. INAMI/RIZIV Belgian tariff data 2011, Available from URL: http://www.riziv.fgov.be/homenl.htm.
22. Arbyn M., Kyrgiou M., Simoens C., Raifu A.O., Koliopoulos G., Martin-Hirsch P., et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. Br Med J 2008, 337:a1284.
23. ISPOR Pharmacoeconomic guidelines around the world 2010 2010, Available from URL: http://www.ispor.org/PEguidelines/index.asp [cited 23.09.2010].
24. Cleemput I., Van Wilder P., Vrijens F., Huybrechts M., Ramaekers D. Richtlijnen voor farmaco-economische evaluaties in België - Recommandations pour les évaluations pharmacoéconomiques en Belgique. KCE reports 78A/B 2008, Federaal Kenniscentrum voor de Gezondheidszorg - Centre Fédéral d'Expertise des Soins de Santé, Brussels.
25. Thiry N., Lambert M.-L., Cleemput I., Huybrechts M., Neyt M., Hulstaert F., et al. HPV vaccination for the prevention of cervical cancer in Belgium: health technology assessment 2007, Federaal Kenniscentrum voor de Gezondheidszorg - Centre Fédéral d'Expertise des Soins de Santé, Brussels.
26. IMF World economic outlook database 2011, Available from URL: http://www.imf.org/external/pubs/ft/weo/2011/02/weodata/weorept.aspx?sy=2009&ey=2016&scsm=1&ssd=1&sort=country&ds=&br=1&c=124&s=NGDPRPC%2CNGDPPC&grp=0&a=&pr1.x=73&pr1.y=14 [cited 26.03.2012].
27. Wheeler C. Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in reducing abnormal cytology and against lesions associated with vaccine and non-vaccine oncogenic types: an analysis of women negative for specific HPV types at baseline [abstract P VC-2]. Abstract presented at The European Research Organisation on Genital Infection and Neoplasia (EUROGIN) 2010, HPV PATRICIA Study Group.
28. Tjalma W., Paavonen J., Naud P., Wheeler C., Chow S.N., Apter D., et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic HPV-naïve population. Int J Gynecol Cancer 2009, 19(Suppl 2):1008. [abstract 1446].
29. Westra T.A., Rozenbaum M.H., Rogoza R.M., Nijman H.W., Daemen T., Postma M.J., et al. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J Infect Dis 2011, 204(August (3)):377-384.
30. Poppe W.A., Simon P.H., De Ridder M.R. Why consider human papillomavirus vaccination in older women?. Gynecol Obstet Invest 2010, 70(4):237-243.
31. Suarez E., Smith J.S., Bosch F.X., Nieminen P., Chen C.J., Torvinen S., et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine 2008, 26(September (Suppl 5)):F29-F45.
32. Fine P.E. Herd immunity: history, theory, practice. Epidemiol Rev 1993, 15(2):265-302.
33. Jit M., Chapman R., Hughes O., Choi Y.H. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. Br Med J 2011, 343:d5775.
34. Soergel P., Makowski L., Schippert C., Staboulidou I., Hille U., Hillemanns P. The cost efficiency of HPV vaccines is significantly underestimated due to omission of conisation-associated prematurity with neonatal mortality and morbidity. Hum Vaccin Immunother 2012, 8(February (2)):243-251.
35. Boulanger J.C., Sevestre H., Bauville E., Ghighi C., Harlicot J.P., Gondry J. Epidemiology of HPV infection. Gynecol Obstet Fertil 2004, 32(March (3)):218-223.
36. Moscicki A.B., Shiboski S., Broering J., Powell K., Clayton L., Jay N., et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998, 132(February (2)):277-284.
37. Hildesheim A., Schiffman M.H., Gravitt P.E., Glass A.G., Greer C.E., Zhang T., et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994, 169(February (2)):235-240.
38. Myers E.R., McCrory D.C., Nanda K., Bastian L., Matchar D.B. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000, 151(12):1158-1171.
39. Moscicki A.B., Hills N., Shiboski S., Powell K., Jay N., Hanson E., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. J Am Med Assoc 2001, 285(June (23)):2995-3002.
40. Hulstaert F., Arbyn M., Huybrechts M., Vinck I., Puddu M., Ramaekers D. Cervical cancer screening and human papillomavirus (HPV) testing. KCE report 38 2006.
41. Melnikow J., Nuovo J., Willan A.R., Chan B.K., Howell L.P. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998, 92(October (4 Pt 2)):727-735.
42. Nobbenhuis M.A., Helmerhorst T.J., van den Brule A.J., Rozendaal L., Voorhorst F.J., Bezemer P.D., et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001, 358(November (9295)):1782-1783.
43. Van Eycken E. Cancer incidence and survival in Flanders, 2000-2001 2006, Flemish League against Cancer (Vlaamse Liga tegen Kanker, VLK), Brussels.
44. Statistics Belgium 2010, Available from URL: www.statbel.fgov.be.
45. Appendix 11: human papillomavirus. In Stratton KR, Durch JS, Lawrence S, editors. Vaccines for the 21st century: a tool for decision-making. Washington, DC: National Academy Press; 2000. p. 213-21.
46. Gold M.R., Franks P., McCoy K.I., Fryback D.G. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998, 36(June (6)):778-792.
47. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004, 96(8):604-615.
48. Insinga R., Glass A., Rush B. Health state transitions following an abnormal pap smear: implications for health utility assessment in cost-effectiveness analyses. Presented at 22nd international papillomavirus conference & clinical workshop 2005 2005, [abstract W-02].
49. Myers E.R., Green S., Lipkus I. Patient preferences for health states related to HPV infection: visual analog scale versus time trade-off elicitation. Presented at the twenty-first international papillomavirus conference 2004, [abstract no. 542].
50. World Health Organization, Institut Catala d'Oncologia WHO/ICO Information Centre on human papillomavirus and cervical cancer 2011, Available from URL: http://apps.who.int/hpvcentre/statistics/dynamic/ico/DataQuerySelect.cfm [cited May 2011].
51. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364(November (9447)):1757-1765.